AtriCure Announces the First Patient Treated in the LeAAPS™ Clinical Trial

Author's Avatar
Jan 31, 2023

AtriCure%2C+Inc. (Nasdaq%3A+ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the first patient was treated in the Left Atrial Appendage Exclusion for Stroke Prevention (LeAAPS™) clinical trial (NCT 05478304). The patient was treated by U.S. co-principal investigator Dr. Marc Gerdisch at Franciscan St. Francis Heart Center in Indianapolis, Indiana.